Cellular Mechanisms Underlying Melanoma Brain Metastasis
Preprint
Abstract
Brain metastasis is a major contributor to melanoma-related mortality, arising from both genomic alterations and dynamic adaptations to the brain microenvironment. Tumor cells must cross the blood–brain barrier and exploit brain-specific signaling and metabolic landscapes to establish metastases. Brain metastases display molecular and phenotypic programs distinct from other organs, reflecting pre-existing and acquired mutations during progression. We analyzed primary melanoma, metastatic melanoma, and metastatic brain tumors genomic datasets to identify mutated proteins and signaling pathways that are common to or distinct among these tumor types. Our comprehensive computational analyses uncovered key pathways and proteins associated with brain metastasis. Brain metastases exhibit unique mutational landscapes and convergent alterations in neurotrophin, MAPK, and PI3K/AKT signaling compared with primary and metastatic melanoma. Proteins especially frequent in brain metastases pathways support survival, proliferation, and adaptation in the brain microenvironment. Pharmacology-wise, rational strategies such as combining c-KIT and VEGFR inhibitors can suppress converging oncogenic pathways and mitigate resistance in advanced melanoma. Co-targeting neurotrophin receptors with MAPK pathway members, particularly in combination with BRAF inhibitors, appears a promising approach for treating melanoma brain metastases. Our findings underscore the molecular heterogeneity of melanoma brain metastases, shaped by interconnected signaling networks , and reveal therapeutic targets that may diverge from those in other metastatic sites .Keywords
Funding Information
- National Institutes of Health (HHSN261201500003I)
This publication has 112 references indexed in Scilit:
- Targeting VEGF signaling for tumor microenvironment remodeling and metastasis inhibition: Therapeutic strategies and insightsBiomedicine & Pharmacotherapy, 2025
- Activation mechanisms of clinically distinct B‐Raf V600E and V600K mutantsCancer Communications, 2022
- Tumor suppressor p53: Biology, signaling pathways, and therapeutic targetingBiochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2021
- Tumor angiogenesis: causes, consequences, challenges and opportunitiesCellular and Molecular Life Sciences, 2019
- The biology and therapeutic management of melanoma brain metastasesBiochemical Pharmacology, 2018
- Cancer metastasizes to the bone marrow and not to the bone: time for a paradigm shift!European Journal of Nuclear Medicine and Molecular Imaging, 2018
- Functional KRAS mutations and a potential role for PI3K/AKT activation in Wilms tumorsMolecular Oncology, 2017
- Targeting hyperactivation of the AKT survival pathway to overcome therapy resistance of melanoma brain metastasesCancer Medicine, 2012
- p75 neurotrophin receptor functions as a survival receptor in brain‐metastatic melanoma cellsJournal of Cellular Biochemistry, 2003
- Expression of neurotrophins and the trk family of neurotrophin receptors in normal and hypothyroid rat brainMolecular Brain Research, 1994